STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await

All coverage of this event, automatically grouped from multiple independent sources.

Last updated: 1 October 2026 at 13:26 · 6 articles · 1 sources

STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await

The small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody to protect against Covid.

Read at STAT News · 1 October 2026 at 10:30

STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy

Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.

Read at STAT News · 1 October 2026 at 10:30

STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world

A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.

Read at STAT News · 1 October 2026 at 08:30

STAT+: Can a top Republican from a bygone political era fix pharma’s woes in Washington?

In Washington, Eric Cantor will confront bipartisan backlash over rising health care costs.

Read at STAT News · 1 October 2026 at 08:30

STAT+: Two key Senate health committees face major shake-ups

Senate committees that handle important health care matters are about to see major GOP turnover. Here's what that means.

Read at STAT News · 1 October 2026 at 08:30

STAT+: Sanofi, Regeneron expand partnership after Dupixent success

Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.

Read at STAT News · 1 October 2026 at 06:16

More on YardSpinner

Artificial Intelligence Climate Change Technology Football Formula 1 Elections